Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical company Sanofi have signed another partnership to bring digital solutions for insulin management to Japan.
According to a press release, both companies will jointly develop digitized features for insulin in Japan, including connected caps for insulin and titration alerts.
Health2Sync has a mobile health app that is currently used by about 290,000 patients in Japan.
WHY IT MATTERS
A recently A study by the Japan Diabetes Clinical Data Management Study Group found that mean HbA1c levels tend to rise in people with diabetes mellitus. It also found that Japanese patients receive an average of 14.8 units of baseline insulin with 7.8% HbA1c, suggesting that basal insulin dosage can be further optimized through appropriate approaches. However, continuously recording blood glucose levels can be cumbersome for diabetics who are already struggling to control their disease in an unstable environment.
Health2Sync and Sanofi claim that their digital solutions will help improve insulin management among healthcare providers and patients with diabetes in Japan.
This latest partnership “underscores the companies’ commitment to realizing more comprehensive management of chronic diseases through digital solutions,” according to a press statement.
THE BIGGER TREND
Health2Sync and Sanofi first worked in 2020 in a digital health program that has so far provided digital solutions to over 200 clinics and more than 10,000 insulin patients across Asia.
Last year the company expanded their partnership to jointly develop an automated digital insulin management solution with titration algorithms that are now being evaluated for their therapeutic effects.
Both companies continue to have plans to expand their partnership to offer digital therapeutic solutions to patients and healthcare professionals in Japan and other markets.